Top Page
NovaBay Pharma
(NBY)
NovaBay Pharma (NBY) vs. SPDR S&P 500 ETF (SPY)
NovaBay Pharma Business Overview & Revenue Model
NovaBay Pharma Earnings Call Summary
NovaBay Pharma Financial Statement Overview
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 2.83M | 9.78M | 10.46M | 14.40M | 10.20M | 9.93M |
| Gross Profit | 1.51M | 6.48M | 6.08M | 7.78M | 6.51M | 5.96M |
| EBITDA | -7.73M | -5.92M | -4.09M | -7.20M | -8.74M | -6.38M |
| Net Income | 3.24M | -7.22M | -9.64M | -10.61M | -5.82M | -11.04M |
Balance Sheet | ||||||
| Total Assets | 3.49M | 3.42M | 9.03M | 16.40M | 23.98M | 15.24M |
| Cash, Cash Equivalents and Short-Term Investments | 2.31M | 430.00K | 3.13M | 5.36M | 7.50M | 11.95M |
| Total Debt | 970.00K | 1.67M | 2.74M | 2.04M | 551.00K | 503.00K |
| Total Liabilities | 1.85M | 3.55M | 5.72M | 5.84M | 13.81M | 2.92M |
| Stockholders Equity | 1.63M | -129.00K | 3.31M | 10.55M | 10.17M | 12.32M |
Cash Flow | ||||||
| Free Cash Flow | -6.97M | -5.19M | -4.28M | -6.77M | -9.24M | -4.75M |
| Operating Cash Flow | -6.97M | -5.18M | -4.26M | -6.65M | -9.19M | -4.72M |
| Investing Cash Flow | 0.00 | 1.06M | -19.00K | -112.00K | -12.04M | -26.00K |
| Financing Cash Flow | -2.82M | 1.50M | 1.91M | 4.63M | 16.79M | 9.76M |
NovaBay Pharma Technical Analysis
NovaBay Pharma Risk Analysis
NovaBay Pharma Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
53 Neutral | $32.91M | ― | ― | ― | 4455.07% | 77.31% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
43 Neutral | $6.23M | -0.02 | -370.95% | ― | 12.45% | 87.08% | |
41 Neutral | $6.61M | -0.59 | -587.58% | ― | -74.73% | 95.81% | |
39 Underperform | $13.82M | ― | -169.32% | ― | ― | 53.13% | |
38 Underperform | $5.17M | -0.11 | -152.19% | ― | 192.72% | 83.61% |
NovaBay Pharma Corporate Events
NovaBay Pharmaceuticals, Inc. is a Delaware-based company primarily engaged in the development and sale of wound care products, with a focus on manufacturing and exporting to China. Recently, the company has divested its eyecare and skincare businesses, including the sale of its primary trademarks.
NovaBay Pharma held its Annual Meeting of Stockholders on October 16, 2025, where several key decisions were made. The stockholders approved a reverse stock split, which will reduce the number of outstanding shares and potentially affect voting rights and future share issuances. Additionally, significant changes in the company’s leadership were announced, with the resignation of several board members and the appointment of Michael Kazley as the new CEO and Chairman. The company also filed a Certificate of Amendment to increase its authorized shares of common stock, while a proposal to increase preferred stock was not approved.
The most recent analyst rating on (NBY) stock is a Hold with a $1.50 price target. To see the full list of analyst forecasts on NovaBay Pharma stock, see the NBY Stock Forecast page.
On October 9, 2025, NovaBay Pharma entered into a Securities Purchase Agreement with R01 Fund LP and Framework Ventures IV L.P. to transfer shares of Series D and Series E Preferred Stock previously acquired by David Lazar. This transaction is contingent on stockholder approval at the company’s annual meeting on October 16, 2025, and upon completion, the purchasers are expected to collectively own approximately 90% of the outstanding common stock, significantly impacting the company’s ownership structure.
The most recent analyst rating on (NBY) stock is a Hold with a $1.50 price target. To see the full list of analyst forecasts on NovaBay Pharma stock, see the NBY Stock Forecast page.
On September 18, 2025, NovaBay Pharmaceuticals announced a one-time special cash dividend of $0.80 per share for its common stock, payable on September 29, 2025. Due to the dividend’s size, NYSE American advised that the company’s stock will trade with ‘due bills’ during the Dividend Right Period, affecting stockholders’ rights to the dividend. The company also plans to hold its 2025 Annual Meeting on October 16, 2025, to discuss strategic proposals, with CEO David Lazar expressing optimism about future strategic alternatives.
The most recent analyst rating on (NBY) stock is a Hold with a $1.50 price target. To see the full list of analyst forecasts on NovaBay Pharma stock, see the NBY Stock Forecast page.
On August 26, 2025, NovaBay Pharmaceuticals announced a special cash dividend of $0.80 per share, payable on September 29, 2025, to stockholders of record as of September 15, 2025. This decision follows an investment agreement with David E. Lazar, who has committed up to $6 million in exchange for preferred stock. The dividend aims to maximize shareholder value after the sale of NovaBay’s eye care products to PRN Physician Recommended Nutriceuticals, LLC earlier in the year. The NYSE American has advised that the company’s stock will trade with ‘due bills’ during the dividend right period, affecting stockholders who sell their shares during this time.
The most recent analyst rating on (NBY) stock is a Hold with a $1.00 price target. To see the full list of analyst forecasts on NovaBay Pharma stock, see the NBY Stock Forecast page.
NovaBay Pharmaceuticals announced a significant strategic shift following the sale of its eyecare products. On August 19, 2025, the company entered into a $6 million securities purchase agreement with investor David E. Lazar, who was appointed as the new CEO. This move, which includes issuing non-voting convertible preferred stock, is aimed at maintaining NovaBay’s public listing and exploring strategic investment opportunities, rather than pursuing liquidation. The transaction is expected to provide funds for future acquisitions and a special cash dividend for stockholders, marking a new direction for the company.
The most recent analyst rating on (NBY) stock is a Hold with a $0.50 price target. To see the full list of analyst forecasts on NovaBay Pharma stock, see the NBY Stock Forecast page.